Prophylactic Activity of Biogenic Selenium Nanoparticles Against Chronic Toxoplasma gondii Infection

Author(s): Amir Keyhani, Mojtaba Shakibaie, Hossein Mahmoudvand, Sareh Jahanbakhsh, Amir T. Kareshk, Saeedeh Shojaee, Naser Ziaali*

Journal Name: Recent Patents on Anti-Infective Drug Discovery
Continued as Recent Advances in Anti-Infective Drug Discovery

Volume 15 , Issue 1 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Studies showed that biogenic selenium nanoparticles (SeNPs) have a number of pharmacological properties, such as antimicrobial ones.

Objective: The present investigation assesses the efficacy of biogenic selenium nanoparticles (SeNPs) as a new patent against latent toxoplasmosis in a mice model.

Methods: Male BALB/c mice were orally treated with SeNPs at the doses of 2.5, 5, 10 mg/kg once a day for 14 days. On the 15th day, the mice were infected with the intraperitoneal inoculation of 20-25 tissue cysts from the Tehran strain of Toxoplasma gondii. The mean numbers of brain tissue cysts and the mRNA levels of TNF-α, IL-12, IL-10, IFN-γ, and inducible nitric oxide synthase (iNOS) in mice of each tested group were measured. Moreover, serum clinical chemistry factors in treated mice were examined to determine the safety of SeNPs.

Results: The mean number of the brain tissue cysts was significantly (P<0.001) decreased in mice treated with SeNPs at doses 2.5 (n=37), 5 (n=11), and 10 mg/kg (n=3) based on a dose dependent manner compared with the control group (n=587). The mRNA levels of IFN-γ, TNF-α, IL-12, and iNO were significantly increased in mice treated with SeNPs at the doses 10 mg/kg compared with control subgroups (p<0.05). No significant variation (p>0.05) was observed in the clinical chemistry parameters among the mice in the control subgroups compared with groups treated with SeNPs.

Conclusion: The results of the present study showed a new patent in the treatment of toxoplasmosis; so that taking the biogenic selenium nanoparticles in concentrations of 2.5-10 mg/kg for 2 weeks was able to prevent severe symptoms of the toxoplasmosis in a mice model. This indicated the prophylactic effects of SeNPs with no considerable toxicity against latent toxoplasmosis. However, more studies are required to elucidate the correct anti-Toxoplasma mechanisms of SeNPs.

Keywords: Toxoplasma gondii, latent toxoplasmosis, selenium, antimicrobial effects, toxicity, cellular immunity.

[1]
Dubey JP. Toxoplasmosis - a waterborne zoonosis. Vet Parasitol 2004; 126(1-2): 57-72.
[http://dx.doi.org/10.1016/j.vetpar.2004.09.005] [PMID: 15567579]
[2]
Khryanin AA, Reshetnikov OV, Kuvshinova IN. Toxoplasmosis: epidemiology, diagnosis, treatment. Antibiot Khimioter 2015; 60(5-6): 16-21.
[PMID: 26852491]
[3]
Lewis JM, Clifford S, Nsutebu E. Toxoplasmosis in immunosuppressed patients. Rheumatology (Oxford) 2015; 54(11): 1939-40.
[http://dx.doi.org/10.1093/rheumatology/kev115] [PMID: 25969518]
[4]
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis 2012; 44(11): 805-14.
[http://dx.doi.org/10.3109/00365548.2012.693197] [PMID: 22831461]
[5]
Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human toxoplasmosis: a systematic review. Pathog Glob Health 2017; 111(7): 333-42.
[http://dx.doi.org/10.1080/20477724.2017.1370528] [PMID: 28948861]
[6]
Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol 2013; 114: 125-45.
[http://dx.doi.org/10.1016/B978-0-444-53490-3.00008-X] [PMID: 23829904]
[7]
Antczak M, Dzitko K, Długońska H. Human toxoplasmosis-Searching for novel chemotherapeutics. Biomed Pharmacother 2016; 82: 677-84.
[http://dx.doi.org/10.1016/j.biopha.2016.05.041] [PMID: 27470411]
[8]
Keyhani A, Ziaali N, Shakibaie M, et al. Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model. J Med Microbiol 2020; 69(1): 104-10.
[http://dx.doi.org/10.1099/jmm.0.001111] [PMID: 31846412]
[9]
Liu Q, Singla LD, Zhou H. Vaccines against Toxoplasma gondii: status, challenges and future directions. Hum Vaccin Immunother 2012; 8(9): 1305-8.
[http://dx.doi.org/10.4161/hv.21006] [PMID: 22906945]
[10]
Shakibaie M, Khorramizadeh MR, Faramarzi MA, Sabzevari O, Shahverdi AR. Biosynthesis and recovery of selenium nanoparticles and the effects on matrix metalloproteinase-2 expression. Biotechnol Appl Biochem 2010; 56(1): 7-15.
[http://dx.doi.org/10.1042/BA20100042] [PMID: 20408816]
[11]
Joshi SM, De Britto S, Jogaiah S, Ito S-I. Mycogenic selenium nanoparticles as potential new generation broad spectrum antifungal molecules. Biomolecules 2019; 9(9): 419.
[http://dx.doi.org/10.3390/biom9090419] [PMID: 31466286]
[12]
Rayman MP. The importance of selenium to human health. Lancet 2000; 356(9225): 233-41.
[http://dx.doi.org/10.1016/S0140-6736(00)02490-9] [PMID: 10963212]
[13]
Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005; 64(4): 527-42.
[http://dx.doi.org/10.1079/PNS2005467] [PMID: 16313696]
[14]
Whanger PD. Selenium and its relationship to cancer: an update. Br J Nutr 2004; 91(1): 11-28.
[http://dx.doi.org/10.1079/BJN20031015] [PMID: 14748935]
[15]
Kojouri GA, Jahanabadi S, Shakibaie M, Ahadi AM, Shahverdi AR. Effect of selenium supplementation with sodium selenite and selenium nanoparticles on iron homeostasis and transferrin gene expression in sheep: a preliminary study. Res Vet Sci 2012; 93(1): 275-8.
[http://dx.doi.org/10.1016/j.rvsc.2011.07.029] [PMID: 21868048]
[16]
Tran PA, Webster TJ. Selenium nanoparticles inhibit Staphylococcus aureus growth. Int J Nanomedicine 2011; 6: 1553-8.
[PMID: 21845045]
[17]
Yang J, Huang K, Qin S, Wu X, Zhao Z, Chen F. Antibacterial action of selenium-enriched probiotics against pathogenic Escherichia coli. Dig Dis Sci 2009; 54(2): 246-54.
[http://dx.doi.org/10.1007/s10620-008-0361-4] [PMID: 18612820]
[18]
Mézes M, Balogh K. Prooxidant mechanisms of selenium toxicity – a review. Acta Biol Szeged 2009; 53: 15-8.
[19]
Beheshti N, Soflaei S, Shakibaie M, Yazdi MH, Ghaffarifar F, Dalimi A, et al. Efficacy of biogenic selenium nanoparticles against Leishmania major: in vitro and in vivo studies. J Trace Elem Med Biol 2013; 27(3): 203-7.
[http://dx.doi.org/10.1016/j.jtemb.2012.11.002] [PMID: 23219368]
[20]
Mahmoudvand H, Sheibani V, Keshavarz H, Shojaee S, Esmaeelpour K, Ziaali N. Acetylcholinesterase inhibitor improves learning and memory impairment induced by Toxoplasma gondii infection. Iran J Parasitol 2016; 11(2): 177-85.
[PMID: 28096851]
[21]
Mahmoudvand H, Sheibani V, Shojaee S, Mirbadie SR, Keshavarz H, Esmaeelpour K, et al. Toxoplasma gondii infection potentiates cognitive impairments of Alzheimer’s disease in the BALB/c mice. J Parasitol 2016; 102(6): 629-35.
[http://dx.doi.org/10.1645/16-28] [PMID: 27513205]
[22]
Keyhani A, Mahmoudvand H, Shakibaie M, Tavakoli Kareshk A, Nejati J. Seyed Reza Mirbadie, Saeed Sadooghian, Nima Firoozeh, Naser Ziaali. Histopathological and toxicological study of selenium nanoparticles in BALB/c mice. Entomol Appl Sci Lett 2018; 5: 31-5.
[23]
Saraei M, Ghaderi Y, Mosavi T, Shahnazi M, Keshavarz H, Shojaee S. Brain cystogenesiscapacity of Toxoplasma gondii, avirulent Tehran strain in mice. Asian Pac J Trop Dis 2014; 4(2): 739-42.
[http://dx.doi.org/10.1016/S2222-1808(14)60718-0]
[24]
Shakibaie M, Shahverdi AR, Faramarzi MA, Hassanzadeh GR, Rahimi HR, Sabzevari O. Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharm Biol 2013; 51(1): 58-63.
[http://dx.doi.org/10.3109/13880209.2012.710241] [PMID: 23035822]
[25]
Ha TY, Chang KA, Kim JA, Kim HS, Kim S, Chong YH, et al. S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576, AD animal model. PLoS One 2010; 21(5)e8840
[26]
Yazdi MH, Varastehmoradi B, Faghfuri E, Mavandadnejad F, Mahdavi M, Shahverdi AR. Adjuvant effect of biogenic selenium nanoparticles improves the immune responses and survival of mice receiving 4T1 cell antigens as vaccine in breast cancer murine model. J Nanosci Nanotechnol 2015; 15(12): 10165-72.
[http://dx.doi.org/10.1166/jnn.2015.11692] [PMID: 26682463]
[27]
Yazdi MH, Mahdavi M, Faghfuri E, Faramarzi MA, Sepehrizadeh Z, Hassan ZM, et al. Th1 immune response induction by biogenic selenium nanoparticles in mice with breast cancer: preliminary vaccine model. Iranian J Biotechnol 2015; 13(2): 1-9.
[http://dx.doi.org/10.15171/ijb.1056] [PMID: 28959284]
[28]
Mahmoudvand H, Fasihi Harandi M, Shakibaie M, Aflatoonian MR, ZiaAli N, Makki MS, et al. Scolicidal effects of biogenic selenium nanoparticles against protoscolices of hydatid cysts. Int J Surg 2014; 12(5): 399-403.
[http://dx.doi.org/10.1016/j.ijsu.2014.03.017] [PMID: 24686032]
[29]
Dkhil MA, Khalil MF, Diab MSM, Bauomy AA, Santourlidis S, Al-Shaebi EM, et al. Evaluation of nanoselenium and nanogold activities against murine intestinal schistosomiasis. Saudi J Biol Sci 2019; 26(7): 1468-72.
[http://dx.doi.org/10.1016/j.sjbs.2018.02.008] [PMID: 31762611]
[30]
Loomis TA. Essential of toxicology. Philadelphia, PA: Lea and Febige 1968.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Published on: 04 June, 2020
Page: [75 - 84]
Pages: 10
DOI: 10.2174/1574891X15666200604115001
Price: $65

Article Metrics

PDF: 15
HTML: 3
EPUB: 1
PRC: 1